Navigation Links
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Date:5/29/2009

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent solid tumors. The data gathered from both trials are scheduled to be presented at the 45th Annual Meeting of the American Society of Clinical Oncology Annual Meeting in Orlando, Florida, from May 29 to June 2, 2009. Neratinib is an investigational orally administered irreversible inhibitor of the HER-2 and EGFR kinases.

"The data gathered from these studies provide additional evidence suggesting that neratinib, when combined with these therapies, is an active agent in HER-2 positive breast cancer," says Ramona Swaby, M.D., Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA. "While improvements have been made in treating HER-2 positive breast cancer, there remains an unmet medical need for more therapies for patients with metastatic breast cancer. These data warrant ongoing and future investigations to further understand and evaluate the utility of neratinib against this aggressive disease."

Neratinib (HKI-272) in Combination with Trastuzumab for the Treatment of Advanced Breast Cancer

This ongoing phase 1/2 study of neratinib in combination with trastuzumab evaluated patients with advanced ErbB-2 positive breast cancer that progressed following therapy with trastuzumab, the standard of care in this disease setting. The primary endpoint of the two-part study is 16-week progression-free survival (PFS). The first part of
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
2. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
3. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
4. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
5. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
6. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
7. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
10. What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)...   West Pharmaceutical Services, Inc. (NYSE: ... for injectable drug administration, announced today it plans to ... site in Waterford, Ireland . The ... cartridges and other high-value packaging components, in order to ... operational, this new site could bring approximately 150 new ...
(Date:10/1/2014)... Oct. 1, 2014 The Cardinal ... Interested parties can learn about the company,s ... is supporting the health care continuum by ... Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... and the chief executive officer,s letter to ...
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014  ResMed (NYSE: ... people sleep and the first company to design complete sleep ... to educate women about the importance of a good night,s ... initiative will challenge the myth that feeling tired is just ... to understand that sleep is a critical pillar of health, ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3
... , SAN DIEGO, Nov. 25 NuVasive, Inc. (Nasdaq: ... for minimally disruptive surgical treatments for the spine, announced today that ... at 5:30 p.m. ET / 2:30 p.m. PT. The conference ... Company,s products and will include comments from management followed by a ...
... ... a new market research report is available in its ... Trends & Analysis http://www.reportlinker.com/p0164267/Intranasal-Drug-Delivery---US-Market-Trends--Analysis.html , The ... of therapeutic applications from the delivery of conventional local ...
Cached Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... raise your risk for high blood pressure, a new study ... lived within 109 yards of a busy road had a ... women living at least half a mile away, researchers report. ... of our physical environment on our health and well-being," said ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... that pull out all the stops to rescue surgical ... but the cost of such heroism is questionable, a ... 5 percent better at saving elderly patients with life-threatening ... with less intensity, said senior author Dr. Amir Ghaferi. ...
(Date:10/1/2014)... Psychiatry researchers from the University of Adelaide have developed ... likelihood of a good outcome from treatment - from ... based on a range of factors, including clinical symptoms, ... biomarkers in the patient,s blood. , Speaking in the ... the University,s Head of Psychiatry , Professor ...
(Date:10/1/2014)... Journal of the American Medical Association shows ... or severe chronic knee pain, acupuncture did not provide ... randomly assigned 282 patients (50 years or older) with ... pretend laser treatment. , Treatments were delivered for ... and sham (inactive) laser acupuncture. , Researcher Professor Kim ...
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Predicting the future course of psychotic illness 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
... technologies, testing methods, and processes to improve medical decontamination efforts. ... in other industries, and is using that knowledge to help improve ... ... Midbrook, Inc., a Jackson, MI based manufacturer of medical decontamination ...
... SAN ANTONIO, May 12 Eye Care Centers of ... acquired $65,360,000 of ECCA,s 10-3/4 percent Senior Subordinated Notes ... managed and/or advised by DDJ Capital Management, LLC were ... amount, plus accrued interest to the purchase date. The ...
... a meeting today with President Obama and business leaders, ... drew praise for their innovative employee health care and ... the meeting, President Obama referred to the participants, which ... President and CEO Steven Burd, as "some of the ...
... today,s release of the annual Social Security and ... two largest programs are on a troubled fiscal ... together on reforms of both programs aimed at ... to recognize the underlying structural factors contributing to ...
... Minn. -- Mayo Clinic and Grameen Healthcare are ... leveraging Mayo Clinic,s knowledge and expertise in health ... models. A multi-disciplinary team from Mayo Clinic has ... where it was agreed that following an initial ...
... FARMINGDALE, N.Y., May 12 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has announced their attendance and participation in ... held in Los Angeles, CA, March 19-21, 2009. ...
Cached Medicine News:Health News:Midbrook Developing Decontamination Standards for Medical Industry 2Health News:Midbrook Developing Decontamination Standards for Medical Industry 3Health News:President Obama Praises Retailers as Part of the Health Care Solution 2Health News:Concord Coalition Says New Trustees' Report Demonstrates the Importance of Health Care Cost Control 2Health News:Mayo Clinic and Grameen Healthcare join forces to launch demonstration project 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 3
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
... the ISI Lexan Universal K ... table for lower and upper ... and neck, and lower extremity ... package gives you the ability ...
... Our manufacturing process ... flux-density nanocrystals ensuring magnetic ... allied with the rigid ... no magnetic aggregation occurs ...
Medicine Products: